Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance

References

• Bannister AJ, Kouzarides T. 2011. Regulation of chromatin by histone modifications. Cell Res. 21:381–395.
   PubMed Web of Science ®Google Scholar
• Bastian L, Hof J, Pfau M, Fichtner I, Eckert C, Henze G, Prada J, von Stackelberg A, Seeger K, Shalapour S. 2013. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kappaB. Clin Cancer Res. 19:1445–1457.
   PubMed Web of Science ®Google Scholar
• Bhuiyan MP, Kato T, Okauchi T, Nishino N, Maeda S, Nishino TG, Yoshida M. 2006. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg Med Chem. 14:3438–3446.
   PubMed Web of Science ®Google Scholar
• Bieliauskas AV, Pflum MKH. 2008. Isoform-selective histone deacetylase inhibitors. Chem Soc Rev. 37:1402–1413.
   PubMed Web of Science ®Google Scholar
• Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, Younes A. 2008. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood. 112:1424–1433.
   PubMed Web of Science ®Google Scholar
• Cao DJ, Wang ZV, Battiprolu PK, Jiang N, Morales CR, Kong Y, Rothermel BA, Gillette TG, Hill JA. 2011. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci USA. 108:4123–4128.
   PubMed Web of Science ®Google Scholar
• Carrato A. 2008. Adjuvant treatment of colorectal cancer. Gastrointest Cancer Res. 2:S42–S46.
   PubMedGoogle Scholar
• Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
   PubMedGoogle Scholar
• Chun P. 2015. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res. 38:933–949.
   PubMed Web of Science ®Google Scholar
• Cobanoglu U, Sonmez M, Ozbas HM, Erkut N, Can G. 2010. The expression of LMO2 protein in acute B-cell and myeloid leukemia. Hematology. 15:132–134.
   PubMed Web of Science ®Google Scholar
• Colussi C, Mozzetta C, Gurtner A, Illi B, Rosati J, Straino S, Ragone G, Pescatori M, Zaccagnini G, Antonini A, et al. 2008. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA. 105:19183–19187.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, et al. 2012. Ponatinib in refractory philadelphia chromosome-positive leukemias. N Engl J Med. 367:2075–2088.
   PubMed Web of Science ®Google Scholar
• de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. 2003. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 370:737–749.
   PubMed Web of Science ®Google Scholar
• Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD. 2009. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer. 125:463–473.
   PubMed Web of Science ®Google Scholar
• Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. 1999. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 401:188–193.
   PubMed Web of Science ®Google Scholar
• Fischle W, Kiermer V, Dequiedt F, Verdin E. 2001. The emerging role of class II histone deacetylases. Biochem Cell Biol. 79:337–348.
   PubMed Web of Science ®Google Scholar
• Galmozzi A, Mitro N, Ferrari A, Gers E, Gilardi F, Godio C, Cermenati G, Gualerzi A, Donetti E, Rotili D, et al. 2013. Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes. 62:732–742.
   PubMed Web of Science ®Google Scholar
• Ganai SA. 2015. HDAC inhibitors entinostat and suberoylanilide hydroxamic acid (SAHA): the ray of hope for cancer therapy. Mole Life Sci. 1–16.
   Google Scholar
• Ganai SA. 2016. Panobinostat: the small molecule metalloenzyme inhibitor with marvelous anticancer activity. Curr Top Med Chem. 16:427–434.
   PubMed Web of Science ®Google Scholar
• Ganai SA, Kalladi SM, Mahadevan V. 2015. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells. J Biomol Struct Dyn. 33:1185–1197.
   PubMed Web of Science ®Google Scholar
• Ganai SA, Shanmugam K, Mahadevan V. 2015. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of class II HDAC isoforms. J Biomol Struct Dyn. 33:374–387.
   PubMed Web of Science ®Google Scholar
• Gibbs A, Schwartzman J, Deng V, Alumkal J. 2009. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci USA. 106:16663–16668.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Chuah C, Wilding G, Chang J, Verstovsek S, Faderl S, Kantarjian HM, Ethirajulu K, Zhu J. 2010. Phase I study of the oral histone deacetylase inhibitor SB939 in patients with advanced hematologic malignancies. Blood 116. Abstract no. 3292.
   Web of Science ®Google Scholar
• Garcia-Manero G, Atallah E, Khaled SK, Arellano M, Patnaik MM, Butler TA, Ashby C, Medeiros BC. 2015. Updated results from a phase 2 study of pracinostat in combination with azacitidine in elderly patients with acute myeloid leukemia. EHA Annual Congress, Poster.
   Google Scholar
• Haberland M, Montgomery RL, Olson EN. 2009. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 10:32–42.
   PubMed Web of Science ®Google Scholar
• Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, et al. 2011. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 25:1751–1759.
   PubMed Web of Science ®Google Scholar
• Hart S, Goh KC, Novotny-Diermayr V, Tan YC, Madan B, Amalini C, Ong LC, Kheng B, Cheong A, Zhou J, et al. 2011. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 1:e44.
   PubMed Web of Science ®Google Scholar
• Hind R, Rew DR, Johnson CD. 1992. Surgical excision alone is adequate treatment for primary colorectal cancer. Ann R Coll Surg Engl. 74:63–67.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 16:2190–2196.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. 2014. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 89:547–556.
   PubMed Web of Science ®Google Scholar
• Johannessen CU, Johannessen SI. 2003. Valproate: past, present, and future. CNS Drug Rev. 9:199–216.
   PubMedGoogle Scholar
• Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, Blaheta RA. 2009. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med. 13:2376–2385.
   PubMed Web of Science ®Google Scholar
• Kalyaanamoorthy S, Chen YP. 2013. Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes. Biochim Biophys Acta. 1834:317–328.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, et al. 2002. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:645–652.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. 2006. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 145:913–923.
   PubMed Web of Science ®Google Scholar
• Kazantsev AG, Thompson LM. 2008. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 7:854–868.
   PubMed Web of Science ®Google Scholar
• Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, et al. 2008. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 409:581–589.
   PubMed Web of Science ®Google Scholar
• Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. 1993. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem. 268:22429–22435.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Bae SC. 2011. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 3:166–179.
   PubMed Web of Science ®Google Scholar
• Korolev N, Allahverdi A, Lyubartsev AP, Nordenskiold L. 2012. The polyelectrolyte properties of chromatin. Soft Matter. 8:9322–9333.
   Web of Science ®Google Scholar
• Kurdistani SK, Grunstein M. 2003. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol. 4:276–284.
   PubMed Web of Science ®Google Scholar
• Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, et al. 2005. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer. 103:1659–1669.
   PubMed Web of Science ®Google Scholar
• Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, et al. 2005. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 11:1–15.
   PubMed Web of Science ®Google Scholar
• Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, Giaccone G, Pommier Y, Bates SE, Varticovski L. 2011. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle. 10:3119–3128.
   PubMedGoogle Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. 2008. Cancer-related inflammation. Nature. 454:436–444.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Pierotti MA. 2008. Cancer and inflammation: a complex relationship. Cancer Lett. 267:180–181.
   PubMed Web of Science ®Google Scholar
• Mishra J, Drummond J, Quazi SH, Karanki SS, Shaw JJ, Chen B, Kumar N. 2013. Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit Rev Oncol Hematol. 86:232–250.
   PubMed Web of Science ®Google Scholar
• Mottamal M, Zheng S, Huang TL, Wang G. 2015. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 20:3898–3941.
   PubMed Web of Science ®Google Scholar
• Novotny-Diermayr V, Hart S, Goh KC, Cheong A, Ong LC, Hentze H, Pasha MK, Jayaraman R, Ethirajulu K, Wood JM. 2012. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2:e69.
   PubMed Web of Science ®Google Scholar
• Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, Greicius G, Pettersson S, Liang AL, Loh YK, et al. 2010. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 9:642–652.
   PubMed Web of Science ®Google Scholar
• Nowak SJ, Corces VG. 2004. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet. 20:214–220.
   PubMed Web of Science ®Google Scholar
• Okabe S, Tauchi T, Tanaka Y, Kimura S, Maekawa T, Ohyashiki K. 2013. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 13:32.
   PubMed Web of Science ®Google Scholar
• Peng L, Seto E. 2011. Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handb Exp Pharmacol. 206:39–56.
   PubMedGoogle Scholar
• Prebet T, Vey N. 2011. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 20:287–295.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. 2010. Third-generation tyrosine kinase inhibitors and beyond. Semin Hematol. 47:371–380.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. 2012. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 36:1124–1127.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Santos FP, Garcia-Manero G. 2011. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 25:226–235.
   PubMed Web of Science ®Google Scholar
• Razak ARA, Hotte SJ, Siu LL, Chen EX, Hirte HW, Powers J, Walsh W, Stayner LA, Laughlin A, Novotny-Diermayr V, et al. 2011. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer. 104:756–762.
   PubMed Web of Science ®Google Scholar
• Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, McLaughlin K, Siddiq A, Kozikowski AP, Jaffrey SR, Twiss JL, et al. 2009. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA. 106:19599–19604.
   PubMed Web of Science ®Google Scholar
• Ropero S, Esteller M. 2007. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25.
   PubMed Web of Science ®Google Scholar
• Shao Y, Gao Z, Marks PA, Jiang X. 2004. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA. 101:18030–18035.
   PubMed Web of Science ®Google Scholar
• Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV. 2006. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 66:7370–7377.
   PubMed Web of Science ®Google Scholar
• Tampakis A, Tampaki EC, Nebiker CA, Kouraklis G. 2014. Histone deacetylase inhibitors and colorectal cancer: what is new? Anticancer Agents Med Chem. 14:1220–1227.
   PubMed Web of Science ®Google Scholar
• Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW. 2010. CYT387, a novel JAK2 inhibitor induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 115:5232–5240.
   PubMed Web of Science ®Google Scholar
• Ververis K, Hiong A, Karagiannis TC, Licciardi PV. 2013. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics. 7:47–60.
   PubMedGoogle Scholar
• Witt O, Deubzer HE, Milde T, Oehme I. 2009. HDAC family: what are the cancer relevant targets? Cancer Lett. 277:8–21.
   PubMed Web of Science ®Google Scholar
• Yong WP, Goh BC, Soo RA, Toh HC, Ethirajulu K, Wood J, Novotny-Diermayr V, Lee SC, Yeo WL, Chan D, et al. 2011. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann Oncol. 22:2516–2522.
   PubMed Web of Science ®Google Scholar
• Zhang CZ, Zhang HT, Chen GG, Lai PB. 2011. Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment. Apoptosis. 16:683–695.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Reinberg D. 2001. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 15:2343–2360.
   PubMed Web of Science ®Google Scholar